Zimmerman S W, Johnson C A
Department of Medicine, University of Wisconsin, Madison.
Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):38-41.
Erythropoietin (Epo) is currently used less extensively in peritoneal dialysis (PD) patients than in hemodialysis (HD) patients. Early data suggest that Epo is equally effective in PD patients, and that the risk profile is similar. No adverse consequences to the dialysis procedure or peritonitis rates have been consistently noted. It has been suggested that PD patients may require less Epo than their HD counterparts, but this is unproven. Further research on the preferred route of administration and timing of the dosing is necessary.
目前，促红细胞生成素（Epo）在腹膜透析（PD）患者中的使用不如在血液透析（HD）患者中广泛。早期数据表明，Epo在PD患者中同样有效，且风险特征相似。尚未一直观察到对透析程序或腹膜炎发生率有不良影响。有人提出，PD患者可能比HD患者需要更少的Epo，但这尚未得到证实。有必要对首选给药途径和给药时间进行进一步研究。
